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Fibroblast growth factor-23 (FGF23) is a hormone
indispensable for maintaining phosphate homeostasis. In
response to phosphate intake, FGF23 is secreted from
osteocytes/osteoblasts and acts on the kidney to increase
urinary phosphate excretion. However, the mechanism by
which these cells sense phosphate intake remains elusive.
Calciprotein particles are nanoparticles of calcium-
phosphate precipitates bound to serum protein fetuin-A
and are generated spontaneously in solution containing
calcium, phosphate, and fetuin-A to be dispersed as
colloids. In cultured osteoblastic cells, increase in either
calcium or phosphate concentration in the medium
induced FGF23 expression, which was dependent on
calciprotein particle formation. When transition of calcium-
phosphate precipitates from the amorphous phase to the
crystalline phase was blocked by bisphosphonate, the
calciprotein particle size was reduced and FGF23
expression was augmented, suggesting that small
calciprotein particles containing amorphous calcium-
phosphate precipitates function as a more potent FGF23
inducer than larger calciprotein particles containing
crystalline calcium-phosphate precipitates. In mice, bolus
phosphate administration by oral gavage transiently
increased circulating calciprotein particle levels followed by
a modest increase in FGF23 expression and serum FGF23
levels. However, continuous dietary phosphate load
induced robust and persistent increase in circulating
calciprotein particles and FGF23 levels. We confirmed by
in vivo imaging that calciprotein particles injected
intravenously extravasated into the bone marrow and were
deposited on the inner surface of the bone, indicating that
these particles have direct access to osteoblasts. Thus, we
propose that osteoblasts induce FGF23 expression and
secretion when they sense an increase in extracellular
calciprotein particles following phosphate ingestion.
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P hosphorus homeostasis at the organismal level ismaintained by balancing phosphate intake and excre-tion. Specifically, the amount of phosphate excreted into
urine is regulated so as to become equal to the amount of
phosphate absorbed from the digestive tract.1 The amount of
urinary phosphate excretion is primarily regulated by the
endocrine axis consisting of fibroblast growth factor-23
(FGF23) and its obligate coreceptor klotho. FGF23 is a hor-
mone secreted from osteoblasts and osteocytes in response to
phosphate intake. FGF23 binds to the binary complex of FGF
receptor and klotho expressed in renal tubules and suppresses
phosphate reabsorption, thereby promoting urinary phos-
phate excretion.2 However, it is not clear how osteocytes/
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Translational Statement
Calciprotein particles are colloidal nanoparticles of
calcium-phosphate dispersed in the blood. Calciprotein
particles are increased in patients with chronic kidney
disease and are regarded as pathological agents that
induce inflammatory responses and vascular calcifica-
tion. On the other hand, circulating levels of a bone-
derived phosphaturic hormone fibroblast growth
factor-23 are also increased with chronic kidney disease
progression and are associated with mineral bone dis-
order. In this study, we show that calciprotein particles
function as a physiological agent that delivers calcium-
phosphate to the bone and induces fibroblast growth
factor-23 expression in osteoblasts. The measurement of
blood calciprotein particles levels is expected to be
useful not only for a better understanding on how
fibroblast growth factor-23 production/secretion is
regulated but also for risk evaluation of chronic kidney
disease–mineral bone disorder.
www.kidney-international.org ba s i c re sea r ch
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osteoblasts sense phosphate intake to induce expression and
secretion of FGF23.
A possible mechanism is that osteoblasts/osteocytes secrete
FGF23 when they sense postprandial increase in the blood
phosphate level through a putative “phosphate-sensing re-
ceptor.” This hypothesis is analogous to the fact that para-
thyroid cells secrete parathyroid hormone (PTH) when they
sense decrease in the blood calcium level through the
calcium-sensing receptor.3 However, several lines of evidence
argue against this hypothesis. First, serum FGF23 levels were
correlated not only with serum phosphate but also with cal-
cium levels.4 Second, increase in serum phosphate failed to
raise serum FGF23 when the serum calcium level was low5
and vice versa. Namely, in the presence of hypo-
phosphatemia, FGF23 was not increased in response to in-
crease in serum calcium.4 These observations indicate that
both serum calcium and phosphate concentration must be
above a certain level to induce FGF23 secretion.
Calciprotein particles (CPP) are colloidal nanoparticles
composed of serum protein fetuin-A laden with calcium-
phosphate precipitates (CaPis) and dispersed in the
blood.6,7 We recently established a method for quantification
of CPPs in the blood and found that plasma CPP levels were
correlated with serum FGF23 and phosphate levels.8 Thus, we
hypothesize that it is not phosphate or calcium per se but
CPPs that may induce FGF23 secretion and/or production in
osteoblasts/osteocytes. The purpose of this study is to test this
hypothesis.
RESULTS
CPP formation is associated with FGF23 induction
To determine whether increase in the extracellular calcium
and phosphate can directly induce FGF23 expression in os-
teoblasts, we cultured rat osteoblastic cells (UMR-106),
increased calcium and phosphate concentration in the me-
dium, and measured cellular FGF23 mRNA levels by quan-
titative reverse transcriptaseQ5 polymerase chain reaction
(qPCR). FGF23 expression was increased not only with in-
crease in phosphate but also with increase in calcium
(Figure 1a). We measured CPP levels in the medium by the
gel filtration method8 and observed a linear correlation be-
tween the CPP and FGF23 mRNA levels (Figure 1b). How-
ever, when formation of CaPis was inhibited by adding citrate
to the medium, both CPP and FGF23 mRNA levels were
decreased (Figure 1c and d), whereas mRNA levels encoded
by other genes, including cyclophilin and cytochrome P450
family 24, were not decreased (data not shown). These results
are consistent with the hypothesis that formation of CPPs in
the medium is necessary for osteoblastic cells to induce
FGF23 expression.
Synthesized CPPs induce FGF23 expression
Next, we tested whether CPPs could increase FGF23 expres-
sion without increasing the calcium and phosphate concen-
tration in the medium. We added synthesized CPPs to the
medium of UMR-106 cells and observed a dose-dependent
increase in FGF23 expression (Figure 2a). The FGF23
mRNA levels were significantly increased within 4 hours after
addition of synthesized CPPs (Figure 2b), followed by in-
crease in the FGF23 protein levels in the conditioned medium
(Figure 2c). Although to a significantly lesser extent than the
CPP treatment, the vehicle treatment also induced FGF23
over time (Figure 2b and c), which may reflect the effect of
1,25-dihydroxyvitamin D3 added to the medium. We
confirmed that addition of synthesized CPPs never increased
but rather reduced the levels of phosphate, calcium, and
calcium phosphate product in the medium before FGF23
expression was induced (Figure 2d–f). We also confirmed that
the CPP levels in the medium stayed constant during the
experimental period (Figure 2g). Hence, we concluded that
persistent increase in the extracellular CPPs, but not increase
in the phosphate or calcium concentration, is necessary and
sufficient for osteoblastic cells to induce FGF23 expression.
Physical property of CPPs affect their ability to induce FGF23
expression
Amorphous CaPis undergo spontaneous transition into the
thermodynamically stable crystalline phase over time.9
Because bisphosphonate interferes with the amorphous-to-
crystalline phase transition of CaPis,10 we speculated that
bisphosphonate might inhibit growth of crystalline CaPis and
thus formation of CPPs, thereby attenuating the effect of
increase in the extracellular calcium and phosphate concen-
tration on FGF23 induction in osteoblasts. Contrary to our
prediction, addition of alendronate to the high calcium (3
mmol/l [mM]), high phosphate (5 mM) medium augmented
FGF23 expression (Figure 3a). These unexpected results led
us to hypothesize that CPPs generated in the presence or
absence of alendronate could be different in quality, which
might have affected the ability of CPPs to induce FGF23
expression. To test this hypothesis, we performed small angle
X-ray scattering analysis and characterized physical properties
of CPPs generated in the high-phosphate, high-calcium me-
dium in the presence and absence of alendronate. Because
CPPs can be dissolved by chelating calcium in the medium
with ethylenediamine tetraacetic acid (EDTA),8 we extracted
the X-ray scattering profile of CPPs by taking the difference
before and after addition of EDTA (Figure 3b and c). In the
absence of alendronate, we identified CPPs with a hydrostatic
diameter of approximately 35 nm or over. By contrast, these
CPPs disappeared in the presence of alendronate. Instead,
smaller CPPs with a diameter of around 9.2 nm were detec-
ted, which appeared as flat particles with platelike shapes
(Figure 3d). Because the size of a single fetuin-A molecule is
w7.1 nm in diameter,11 these small particles are considered
to be CPPs composed of a single fetuin-A molecule that ad-
sorbs amorphous CaPis. In fact, the size of these particles is
comparable with that of calciprotein monomers, described
previously.11 Calciprotein monomers represent fetuin-A
monomers laden with Posner clusters, or Ca9(PO4)6, which
are around 0.9 nm in diameter and deemed as precursors
of amorphous CaPis.11 These observations imply that the
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9.2-nm CPPs containing amorphous CaPis can induce FGF23
expression more robustly than the >35-nm CPPs containing
crystalline CaPis. For simplicity, we designate CPPs as any
colloidal particles of CaPis bound to fetuin-A, regardless of
whether the fetuin-A is a monomer or multimers, although
significant difference may exist between CPPs and calcipro-
tein monomers in terms of function and clearance.
Bolus phosphate ingestion increases blood CPP and FGF23
levels
Provided that osteoblasts produce/secrete FGF23 in
response to phosphate intake by sensing CPPs in the blood,
the following findings should be observed. First, blood CPP
levels should be increased after dietary phosphate intake,
followed by increase in FGF23 mRNA levels in the bone and
FGF23 protein levels in the blood. Second, blood CPPs
should extravasate in the bone marrow and have direct
access to osteoblasts and/or osteocytes. To verify these
predictions, we first administered phosphate in mice (6-
week-old male animals, C57BL/6) by oral gavage and
determined how FGF23 mRNA levels in the bone and
blood levels of phosphate, calcium, CPPs, PTH, 1,25-
dihydroxyvitamin D3, and FGF23 would be changed over
time. Serum FGF23 levels were measured in 2 distinct
assays—c-terminal FGF23 (cFGF23) enzyme-linked
immunosorbent assay (ELISA) and intact FGF23
(iFGF23) ELISA.12 In the cFGF23 ELISA, both the capture
and detection antibodies recognize the C-terminal portion
of FGF23. On the other hand, the iFGF23 ELISA consists of
the capture antibody that binds to the N-terminal portion
and the detection antibody that binds to the C-terminal
portion of FGF23. Because FGF23 is inactivated by pro-
teolytic cleavage to produce the N-terminal and C-terminal
fragments,13 iFGF23 represents the active fraction of
FGF23, whereas cFGF23 represents the total amount of
secreted FGF23 protein including both active and inactive
FGF23.
We observed increase in serum CPP, phosphate, and PTH
levels and decrease in serum calcium levels within 2 hours,
which restored to the basal levels within 4 to 6 hours
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Figure 1 | Induction of fibroblast growth factor-23 (FGF23) expression in cultured osteoblastic cells is associated with calciprotein
particle (CPP) formation in the medium. (a) Induction of FGF23 expression in UMR-106 osteoblastic cells by increasing the extracellular
phosphate and calcium concentration. The FGF23 mRNA levels were quantified by quantitative reverse transcriptase polymerase chain
reaction 24 hours after changing the calcium and phosphate concentration in the medium as indicated. Each bar shows the average of
duplicates. (b) A linear correlation between FGF23 mRNA levels and CPP levels in the conditioned medium. R2 ¼ 0.804, P < 0.0001. (c)
Inhibition of CPP formation by citrate. UMR-106 cells were incubated in the medium containing different concentrations of calcium,
phosphate, and citrate as indicated. Twenty-four hours later, CPP levels in the conditioned medium were determined. Citrate lowered CPP
levels in the medium in a dose-dependent manner. P < 0.013 by analysis of variance, n ¼ 4 for each column. *P < 0.05 versus calcium/
phosphate/citrate ¼ 3/5/0 mmol/l (mM) by t test. (d) Inhibition of CPP formation by citrate-attenuated FGF23 expression induced by
increasing extracellular calcium and phosphate concentration. Citrate lowered FGF23 mRNA levels in a dose-dependent manner.
*P < 0.05 versus calcium/phosphate/citrate ¼ 3/5/0 mM by t test, n ¼ 2w4 for each column. AU, arbitrary unit(s). Q12
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Figure 2 | Calciprotein particles (CPPs) induce fibroblast growth factor-23 (FGF23) expression in cultured osteoblastic cells. (a)
Synthesized CPPs induce FGF23 expression in a dose-dependent manner. P < 0.0001 by analysis of variance, n ¼ 3 for each column. CPPs
were synthesized and prepared as described in the Methods. The indicated doses of synthesized CPPs were added to the medium.
Twenty-four hours later, the cellular FGF23 mRNA levels were measured by quantitative reverse transcriptase polymerase chain reaction.
(b) A time course of FGF23 induction by synthesized CPPs. The cellular FGF23 mRNA levels were quantified by quantitative reverse
transcriptase polymerase chain reaction at the indicated time points after addition of 29.7 mg phosphorus/ml of CPPs (solid columns) or
vehicle (open columns) to the medium. *P < 0.05 versus vehicle by t test, n ¼ 4w8 for each column. (c) A time course of CPP-induced
increase in FGF23 secretion into the medium. FGF23 protein levels in the conditioned medium were quantified by enzyme-linked
immunosorbent assay for C-terminal FGF23 at the indicated time points after addition of 29.7 mg phosphorus/ml of CPPs (solid columns)
or vehicle (open columns) to the medium. The conditioned medium was concentrated before being subjected to the enzyme-linked
immunosorbent assay. *P < 0.05 versus vehicle by t test, n ¼ 4w8 for each column. Levels of (d) phosphate, (e) calcium, (f) calcium
phosphate product, and (g) CPPs in the conditioned medium at the indicated time points after addition of 29.7 mg phosphorus/ml
of CPPs (solid columns) or vehicle (open columns) to the medium. *P < 0.05 versus vehicle by t test, n ¼ 4w9 for each column.
AU, arbitrary unit(s); M, mol/l.
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(Figure 4a–d). In contrast, FGF23 mRNA levels and serum
FGF23 levels were not increased significantly until 4 hours
after the phosphate ingestion (Figure 4e–g), indicating that
increase in plasma CPP levels preceded the increase in
FGF23. The similar time course was observed in the serum
1,25-dihydroxyvitamin D3 levels (Figure 4h). Although
1,25-dihydroxyvitamin D3 has the ability to induce
FGF23 expression in osteoblasts,14 the increase in 1,25-
dihydroxyvitamin D3 cannot explain the increase in
serum FGF23 levels, because the FGF23 mRNA levels
showed a decreasing trend when the 1,25-dihydroxyvitamin
D3 levels were increased. These observations suggest that
CPPs, but not 1,25-dihydroxyvitamin D3, may primarily
contribute to FGF23 induction on bolus phosphate
ingestion.
Blood CPPs extravasate in the bone marrow
Blood CPP and phosphate levels started increasing within 2
hours after the phosphate gavage and returned to the basal
level within 4 hours, indicating that CPPs and phosphates
were cleared from the blood. Because CPPs are nanoparticles,
it is implausible that such large particles are filtrated through
glomerulus and excreted into urine like phosphate is. How-
ever, it is possible that CPPs may exit from blood vessels
through sinusoids, which are capillary beds composed of
endothelial cells with large fenestrations. Sinusoids exist in
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Figure 3 | Physical properties of calciprotein particles (CPPs) affect their ability to induce fibroblast growth factor-23 (FGF23)
expression in cultured osteoblasts. (a) Inhibition of the amorphous-to-crystal phase transition of calcium-phosphate precipitates by
alendronate potentiates the ability of CPPs to induce FGF23 expression. UMR-106 cells were cultured in the medium containing the indicated
concentration of calcium, phosphate, and alendronate for 24 hours and then analyzed by quantitative reverse transcriptase polymerase
chain reaction to quantify FGF23 mRNA levels. *P < 0.05 versus calcium/phosphate/alendronate ¼ 3/5/0 mmol/l (mM) by t test, n ¼ 3w4
for each column. Analysis of the small angle x-ray scattering curves by (b) Guinier plots and (c) Kratky plots of the conditioned medium
from UMR-106 cells incubated with calcium/phosphate/alendronate ¼ 3/5/0 mM (red) and 3/5/0.19 mM (blue) for 20 hours. The radius
of gyration Rg of CPPs in the absence and presence of alendronate was estimated as 136.5 and 36 !A, respectively, which correspond
to 17.6 nm and 4.6 nm in hydrostatic radius Rh provided that CPPs are spheres with uniform density (Rh ¼ 1.29 Rg). (d) The double
logarithm plot of CPPs that informs the shape of particles. Fitted lines were approximated as cylindrical (red), flat (blue), and
spherical (green) particles.26
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the liver and the bone marrow. To determine whether CPPs
could extravasate in the liver and the bone marrow, we
administered synthesized CPPs fluorescently labeled with
fluorescein isothiocyanate (FITC)–conjugated alendronate
into mice by tail vein injection and performed in vivo
imaging. We confirmed that injected CPPs were phagocy-
tosed by Kupffer cells in the liver as previously reported15
(Figure 5a– c, Supplementary Movies S1 and S2). By
in vivo imaging of the calvaria, we found that injected CPPs
were deposited on the bone surface facing the marrow
cavity where osteoblasts reside (Figure 5d and e,
Supplementary Movies S3–S5). We conclude that blood
CPPs can exit from blood vessels in the bone and reach
osteoblasts directly.
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Figure 4 | Bolus phosphate ingestion increases blood calciprotein particles (CPPs) and fibroblast growth factor-23 (FGF23) levels
in mice. The time course of changes in (a) plasma CPPs, (b) serum phosphate, (c) serum calcium, (d) serum parathyroid hormone
(PTH), (e) cellular FGF23 mRNA, (f) serum C-terminal FGF23 (cFGF23), (g) serum intact FGF23 (iFGF23), and (h) serum 1,25-dihydroxyvitamin
D3 after administered with phosphate by oral gavage. *P < 0.05 versus 0 hours (before phosphate administration) by t test, n ¼ 8w11
for each column. AU, arbitrary unit(s).
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Dietary phosphate load increases blood CPP and FGF23 levels
Because increase in dietary phosphate intake was reported to
elevate serum FGF23 levels,4 we asked whether plasma CPP
levels would be increased after dietary phosphate load. We
placed mice (8-week-old male, C57BL/6) on a high phosphate
diet containing 2.0% inorganic phosphate for 2 days and
observed that these mice had significantly higher plasma CPP
levels than did mice placed on a regular diet containing 0.35%
inorganic phosphate (Figure 6a). We also found that the di-
etary phosphate load caused significant increase in serum
FGF23 (both cFGF23 and iFGF23), phosphate, PTH, and
1,25-dihydroxyvitamin D3 levels and marginal decrease in
calcium levels in the blood (Figure 6b–g). FGF23 mRNA
levels in the bone were also significantly increased by feeding
the high phosphate diet (Figure 6h). Thus, unlike bolus
phosphate ingestion, continuous dietary phosphate load
causes persistent increase in plasma CPPs and robust increase
in serum FGF23.
DISCUSSION
Plasma CPP levels were increased after phosphate ingestion
(Figures 4a and 6a). Because FGF23 functions as a phos-
phaturic hormone as well as a counterregulatory hormone for
1,25-dihydroxyvitamin D3,
2 FGF23 should exert negative
impact on CPP formation through lowering phosphate con-
centration in the extracellular fluid by inducing phosphaturia
and through inhibiting calcium absorption in the digestive
tract by lowering circulating a1,25-dihydroxyvitamin D3
levels. Thus, the ability of CPPs to induce FGF23 may be
required for a negative feedback loop to prevent increase in
the circulating CPP level, which is associated with vascular
calcification, aortic stiffness, and inflammation in patients
with chronic kidney disease (CKD).16,17
Koppert et al.18 recently reported that synthesized sec-
ondary CPPs were endocytosed by Kupffer cells by intra-
vital 2-photon imaging, which was consistent with the
finding of our in vivo imaging. However, they did not
describe deposition of CPP to the bone. This may be simply
because they did not look at the bone or because the CPPs
used in their studies were different from the CPPs used in
our present study. They used high-density secondary CPPs
precipitated by centrifugation at 20,000g for 20 minutes. In
contrast, we used CPPs that passed through a gel-filtration
spin column with the size-exclusion limit at 40 kDa,8 which
contained not only high-density CPPs equivalent to the
secondary CPPs they used but also low-density CPPs that
were not precipitated by the centrifugation.8 It remains to
be determined whether the low-density CPPs may be
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efficiently deposited to the bone when compared with high-
density secondary CPPs.
In the present mouse study, bolus phosphate ingestion
increased phosphate and CPPs but reciprocally decreased
calcium within 2 hours, which was accompanied by increase
in PTH. These changes were restored to the basal levels within
4 to 6 hours (Figure 4a–d). In contrast to these quick re-
sponses, significant increase in bone FGF23 mRNA and
serum FGF23 levels did not become evident until 4 hours
after the phosphate ingestion when serum phosphate levels
had already started decreasing (Figure 4e–g). This slow
response of FGF23 indicates that the phosphaturic activity of
FGF23 did not contribute to the restoration of serum phos-
phate levels after the bolus phosphate ingestion. This is also
applicable to humans.19 In addition, the ratio of cFGF23 to
iFGF23 (c/iFGF23 ratio), which represents the activity of
proteolytic inactivation of FGF23, was increased followed by
the increase in the FGF23 mRNA level (Supplementary
Figure S1A), suggesting an attempt to attenuate the FGF23
activity. These observations suggest that phosphaturic activity
of PTH may be primarily responsible for the quick restoration
of the serum phosphate level after bolus phosphate ingestion.
Hence, in this context, physiological significance of the
delayed increase in FGF23 is unclear.
In contrast to bolus phosphate ingestion, continuous di-
etary phosphate load by placing mice on high phosphate diet
for 2 days caused persistent and robust increase in CPP and
FGF23 levels (Figure 4a–c). This is consistent with the results
of in vitro experiment showing that induction of FGF23
secretion in cultured osteoblastic cells required incubation
with CPPs for 8 hours or longer (Figure 2c). Additionally,
unlike bolus phosphate ingestion, continuous dietary phos-
phate load significantly decreased the c/iFGF23 ratio
(Supplementary Figure S1B), suggesting an attempt to limit
proteolytic inactivation of FGF23. Reduction of c/iFGF23
ratio is observed under the condition where phosphaturic
activity of FGF23 is required to maintain phosphate ho-
meostasis like Q6CKD.12 In fact, injection of a neutralizing
antibody against FGF23 to CKD mice raised serum phosphate
levels before PTH started decreasing,20 indicating that it is
not PTH but FGF23 that had primarily contributed to
maintaining phosphate homeostasis in CKD. It appears
that PTH and FGF23 are primarily responsible for main-
taining phosphate homeostasis in response to acute and
chronic phosphate load, respectively. In contrast, increase
in c/iFGF23 ratio is observed under the condition where
FGF23 is produced more than is necessary. For example,
administration of bisphosphonate into mice fed high
phosphate diet elevated serum levels of cFGF23, but not
iFGF23, resulting in increase in the c/iFGF23 ratio
(Supplementary Figure S2). This is consistent with the
in vitro finding that treatment with bisphosphonate
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Figure 6 | Dietary phosphate load increases blood calciprotein particles (CPPs) and fibroblast growth factor-23 (FGF23) levels in
mice. Mice were placed on diet containing 0.35% (NP) or 2.0% (HP) inorganic phosphate for 2 days and then used for measurement of (a)
plasma CPPs, (b) serum C-terminal FGF23 (cFGF23), (c) serum intact FGF23 (iFGF23), (d) serum phosphate, (e) serum calcium, (f) serum
parathyroid hormone (iPTH), (g) serum 1,25-dihydroxyvitamin D3, and (h) cellular FGF23 mRNA levels. *P < 0.05 versus NP by t test,
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increased FGF23 expression in osteoblastic cells cultured in
high phosphate medium (Figure 3a).
The mechanism by which CPPs induce FGF23 and in-
flammatory responses including upregulation of the osteo-
pontin21 and dentin matrix protein-122 (Supplementary
Figure S3) in osteoblasts remains to be determined. Hori
et al.23 reported that induction of FGF23 expression in UMR-
106 cells by increasing phosphate in the medium was
dependent on production of reactive oxygen species (ROS)
and that increase in FGF23 expression induced by hydrogen
peroxide was blocked by a mitogen-activated protein kinase
inhibitorQ7 PD98059. Because CPPs were reported to stimulate
ROS production in cultured macrophages24 and vascular
smooth muscle cells,25 it is plausible that induction of FGF23
expression in osteoblasts by CPPs may be also mediated
through ROS production followed by activation of the
mitogen-activated protein kinase pathway. Therefore, we
tested whether increase in FGF23 expression by CPPs might
be also blocked by PD98059. However, the effect of PD98059
on CPP-induced increase in FGF23 expression was modest
(Supplementary Figure S4), indicating that factors other than
ROS might contribute to increase in FGF23 expression
induced by CPPs.
METHODS
Animals
For the bolus phosphate ingestion experiment, mice (C57BL/6, 6-
week-old males) were starved overnight, administered with 10 ml/g
body weight of 0.5 M phosphate buffer (mixture of 0.5 M NaH2PO4
and 0.5 M Na2HPO4, pH 7.4) by oral gavage, and killed at the
indicated time points to harvest the blood and calvaria. For the
continuous dietary phosphate load experiment, mice (C57BL/6, 8-
week-old male) were placed on either a regular diet containing
0.35% inorganic phosphate or a high phosphate diet containing
2.0% inorganic phosphate for 2 days and then sacrificed to harvest
the blood and calvaria. For bisphosphonate treatment, we placed
C57BL6 male mice at 12 weeks of age on the regular diet or the high
phosphate diet for 10 days. Mice placed on high phosphate diet were
treated with either alendronate (10 mg/kg, s.c. injection) or vehicle
(saline) every other day. All animal experiments were approved by
the institutional animal care and use committee from Jichi Medical
University.
Cell culture
A rat osteoblastic cell line UMR-106 was purchased from ATCC
(CRL-1661; ManassasQ8 , VA) and cultured in growth medium con-
sisting of Dulbecco’s Modified Eagle’s Medium ([DMEM]; Nacalai
Tesque, Kyoto, Japan) supplemented with 10% fetal bovine serum
(Biological Industries, Beit Haemek, Israel). When the cells reached
near-confluency on 12-well plates (Corning, Corning, NY), the
growth medium was replaced with the experimental medium (1 ml/
well) consisting of DMEM containing 40 mg/ml of bovine serum
albumin (Sigma-Aldrich, St. Louis, MO), 0.5 mg/ml bovine fetuin-A
(Sigma-Aldrich), and 1 nM of 1,25-dihydroxyvitamin D3 (Sigma-
Aldrich). Twenty-four hours later, the medium was replaced with the
experimental medium (1 ml/well) containing indicated calcium and
phosphate concentration and further incubated for indicated time
periods.
Preparation of the high phosphate high calcium medium
The concentration of calcium and phosphate in DMEM is 1.8 mM
and 0.9 mM, respectively. The experimental medium containing
higher calcium and phosphate concentration was prepared as fol-
lows: First, calcium-free and phosphate-free DMEM (In Q9) were sup-
plemented with 40 mg/ml of bovine serum albumin, 0.5 mg/ml
bovine fetuin-A, 10 mM N-2-hydroxyethylpiperazine-N0-2-
ethanesulfonic acid (pH 7.4), and 1 nM of 1,25-dihydroxyvitamin
D3. Second, 1 M phosphate buffer was added to the calcium-free
DMEM to bring the phosphate concentration to 2-fold higher
than the desired final concentration. Likewise, 1 M CaCl2 was added
to the phosphate-free DMEM to bring the calcium concentration to
2-fold higher than the desired final concentration. Lastly, the
calcium-free DMEM and the phosphate-free DMEM were mixed in
the volume ratio of 1:1.
Quantification of FGF23 mRNA levels
UMR-106 cells on the plate were washed with phosphate-buffered
saline and then homogenized with RNAiso Plus (TaKaRa Bio Inc.,
Shiga, Japan). Mouse calvaria was frozen in liquid nitrogen and then
crushed using Cryo-Press (MICROTEC Co., Ltd., Chiba, Japan)
before being homogenized with RNAiso Plus. The lysate was
transferred to a microcentrifuge tube and extracted with chloroform.
RNA in the aqueous phase was precipitated with isopropanol,
washed with 75% ethanol, and dissolved in RNase-free water.
Reverse transcription of RNA (0.4 mg) was carried out using
ReverTra Ace qPCR RT Master Mix with gDNA Remover (FSQ-301;
Toyobo Co., Ltd., Osaka, Japan) according to the manufacturer’s
protocol. qPCR reactions contained 20 ng of cDNA, 410 nM of each
primer, and 6 ml of SYBR Green PCR Master mix (THUNDERBIRD
SYBR qPCR Mix QPS-201, Toyobo) in a total volume of 12 ml. The
PCR reaction (95 "C for 1 minute followed by 45 cycles of 95 "C for
10 seconds, 60 "C for 40 seconds) was performed on a LightCycler
480 system (Roche Diagnostics, Rotkreuz, Switzerland). Relative
mRNA levels were calculated by the comparative threshold cycle
method using cyclophilin as an internal control. The nucleotide
sequence of the primers were GCCAGTGGACGCTAGAGAAC (for-
ward) and TGATGCTTCGGTGACAGGTA (reverse) for FGF23,
GATCGATAGTGCCGAGAAGC (forward) and TGAAACTCGTGGCT
CTGATG (reverse) for osteopontin, TCCAGTGAAGACAGCACGTC
(forward) and CATCACTGTGGTGGTCCTTG (reverse) for dentin
matrix protein-1.
CPP assay
Quantification of CPPs in the cell culture medium and mouse blood
was performed as previously reported.8 Briefly, a fluorescent probe
that binds to CaPi crystals (OsteoSense 680EX; PerkinElmer Inc.,
Waltham, MA) was added to concentrated medium or heparin
plasma samples. After incubation at 25 "C for 60 minutes, the
sample was applied to a gel-filtration spin column to remove un-
bound OsteoSense. The fluorescent intensity of the flow-through was
quantified using an infrared fluorescence scanner (Odyssey CLx; LI-
COR Biosciences, Lincoln, NE).
CPP synthesis
Phosphate-free DMEM and calcium-free DMEM were supplemented
with 40 mg/ml of bovine serum albumin and 0.5 mg/ml bovine
fetuin-A. CPPs were synthesized by mixing 20 ml of the phosphate-
free DMEM with its calcium concentration adjusted at 6 mM and the
same volume of the calcium-free DMEM with its phosphate con-
centration adjusted at 10 mM to make the final concentration of
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calcium and phosphate at 3 mM and 5 mM, respectively. The
mixture was incubated at 37 "C for 16 hours and then centrifuged at
16,000g for 2 hours. After removal of the supernatant, the precipi-
tated CPPs were suspended with 0.4 ml of the experimental medium
(1.8 mM calcium, 0.9 mM phosphate) and applied to UMR-106 cells
grown on 12-well plates at indicated doses. CPPs generated under
these experimental conditions contained 1.66 mg of calcium and 0.99
mg of phosphorus per microliter as determined by inductively
coupled plasma mass spectrometry. Briefly, 100 ml of the CPP
preparation was diluted with 10 ml of concentrated nitric acid (98%)
and digested using Titan MPS microwave (PerkinElmer) according
to the manufacturer’s protocol for digestion of milk. Phosphorus
(P31) and calcium (Ca44) content in the digested samples were
measured using inductively coupled plasma mass spectrometry
Nexion 2000 (PerkinElmer) by the kinetic energy discrimination
mode with helium and argon as the collision gas and reaction gas,
respectively. Calibration curves were generated using standards
for calcium and phosphorus (PerkinElmer) at 0.10, 0.99, and
10.00 mg/l.
Small angle X-ray scattering
Small angle X-ray scattering analysis was performed using NANO-
PIX (Rigaku, The Woodlands, TX). Scattering intensities I(h) were
obtained for each sample before and after addition of EDTA at the
final concentration of 5 mM. I(h) is the function of momentum
transfer at h ¼ 4p sin q/l, where 2q and l indicate the scattering
angle and the wavelength of X-ray (1!A), respectively. The difference
in I(h) before and after the EDTA treatment was defined as the
scattering from CPPs. The radius of gyration Rg was estimated by
double exponential Guinier analyses where 2 components were
assumed. The Rg value was also estimated from the peak position of
the Kratky plot with the equation as Rg ¼
ffiffi
3
p
=h. The hydrostatic
radius Rh was estimated as Rh ¼
ffiffiffiffiffiffiffi
5=3
p
Rg .
Blood and medium analysis
FGF23 was measured using mouse/rat FGF23 (C-Term) ELISA
(Immutopics International, San Clemente, CA) and intact FGF23
ELISA (KinosQ10 ) according to the manufacturers’ protocols. For
measurement of FGF23 in the conditioned medium of UMR-106
cells, the medium was concentrated using Amicon Ultra centrifu-
gal filters (2 ml, 3K; Merck Millipore, Billerica, MA) before subjected
to the ELISA. PTH was measured using an ELISA kit for mouse PTH
(CEA866Mu; Cloud-Clone, Katy, TX). Calcium and phosphate were
measured using Fuji Dri-Chem slides and the analyzer (Dri-Chem
NX500V; Fuji Holdings, Tokyo, Japan). Active vitamin D (1,25-
dihydroxyvitamin D3) was measured by radio-immunoassay.
In vivo imaging
Twenty (20) ml of 100 mg/ml rhodamin B-dextran (70 kD; Sigma-
Aldrich) and 50 ml of 62.5 mg/ml Hoechst 33342 (Invitrogen,
Thermo Fisher Scientific, Waltham, MA) were administered to
anesthetized mice (C57BL/6, 8-week-old male) by tail vein injection
for visualizing blood vessels and cell nuclei. Alendronate was con-
jugated with FITC and purified by high performance liquid chro-
matography. Purified FITC-alendronate was used to fluorescently
label CPPs. CPPs synthesized as described above were incubated with
FITC-alendronate (final concentration at 5 mM) for 30 minutes at
room temperature and then applied to a gel-filtration spin column to
remove unbound FITC-alendronate. For imaging of the bone, the
skull surface was surgically exposed, and immediately after admin-
istration of FITC-labeled CPPs from external jugular vein, subjected
to in vivo imaging. CPP signals in the bone marrow were detected by
single-photon imaging. A 2-photon image of the same region was
captured to visualize collagen bone by second harmonic generation
signals. For imaging of the liver, the median lobe of the liver was
surgically exposed, and the FITC-labeled CPPs were injected to the
external jugular vein together with 50 ml of Alexafluor 647 anti-
mouse F4/80 antibody (0.5 mg/ml; BioLegend, San Diego, CA) to
label Kupffer cells. Liver cells and CPPs were visualized by single-
photon imaging. All images were acquired by inverted 2-photon
excitation microscopy (A1R-MP; Nikon, Tokyo, Japan).
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